The trademark application Selendrovir was filed by Sabinsa Europe GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on March 7, 2021, and it was registered by office on June 14, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).